arrow
M

Maurizio D'Incalci

Mario Negri Institute for Pharmacological Research
H指数:80
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial

多模态泛肿瘤细胞游离DNA分析用于卵巢癌微小残留病灶检测和风险分层:MITO16a/MaNGO-OV2试验结果

2026-02-260
OAAI
Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial

来曲唑用于激素受体阳性低级别卵巢癌:一项III期试验的初步毒性结果

2025-12-010
PRE
Dual targeting of solid tumors using cytokine-induced killer cells modified with a CAR anti-tenascin C and a secretable EGFRxCD3 bispecific antibody

使用靶向tenascin C的CAR修饰的细胞因子诱导的杀伤细胞和可分泌的EGFRxCD3双特异性抗体对实体瘤进行双重靶向治疗

2025-09-130
OAAI
The transcriptomic fingerprint of cancer response to Tumor Treating Fields (TTFields)

癌症对肿瘤治疗场 (TTFields) 反应的转录组指纹

2025-07-100
OAAI
Immune evasion mechanisms in early-stage I high-grade serous ovarian carcinoma: insights into regulatory T cell dynamics (vol 16, 229, 2025)

早期I期高级别浆液性卵巢癌中的免疫逃逸机制:对调节性T细胞动力学的见解(卷16,229,2025)

2025-05-160
OA
Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB

恶性胸膜瘤相关的炎症微环境通过GPNMB促进肿瘤进展

2025-04-181
OA
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study

接受贝伐单抗联合一线化疗的卵巢癌患者的TP53突变和生存率: MITO16A/MaNGO OV-2研究的结果

2024-10-160
OAAI
Untargeted analysis of plasma tumor fraction is an independent prognostic marker of response to front line chemotherapy in high-grade serous epithelial ovarian cancer: the MITO-16A/MANGO-OV2A clinical trial experience
2024-03-040
PRE
Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer
2023-12-062
OA
Pan cancer transcriptomic response to tumor treating fields (TTFields)
2023-04-040
PRE
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
2023-02-0915
OAAI
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
2022-10-0121
OAAI